Biological
Sinovac PCV13
Sinovac PCV13 is a biological therapy with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
1
33%
Ph phase_3
2
67%
Phase Distribution
1
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
2(66.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Completed1
Not yet recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (33.3%)
Phase 32 (66.7%)
Trials by Status
completed133%
not_yet_recruiting133%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
not_yet_recruitingphase_3
Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)
NCT07593924
recruitingphase_3
Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
NCT06617715
completedphase_1
A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
NCT06183216
Clinical Trials (3)
Showing 3 of 3 trials
NCT07593924Phase 3
Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)
NCT06617715Phase 3
Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
NCT06183216Phase 1
A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3